Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation Combines Amgen's Proprietary Antibodies and Xencor's XmAb® Bispecific Antibody Platform to Develop New Therapeutic CandidatesIncludes Xencor's Preclinical CD38 Bispecific T Cell Engager for Multiple MyelomaXencor to Receive $45 Million Upfront Payment and Up to $1.7 Billion in Clinical, Regulatory and Sales Milestone Payments in Total for Six Programs

THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Xencor, Inc. (Xencor) (NASDAQ: XNCR) announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb® bispecific technology platform. The collaboration includes molecular engineering by Xencor and the preclinical development of bispecific molecules for five programs proposed by Amgen, leveraging XmAb bispecific Fc domains to...